Group 1 - The Hong Kong innovative drug sector is experiencing significant growth, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 4.1% as of 14:55, and notable increases in individual stocks such as CanSino Biologics-B up over 9%, Innovent Biologics up over 8%, and Lepu Biopharma-B up over 7% [1] - The National Healthcare Security Administration announced the approval of 534 drugs for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug list, marking a record high. Additionally, 121 out of 141 drugs in the newly established commercial insurance innovative drug list passed the review, achieving a pass rate of over 80% [1] - The innovative drug payment system is rapidly taking shape, attracting market attention towards investment opportunities in the industry. The recent revision of the Hang Seng Hong Kong Stock Connect Innovative Drug Index excludes CXO companies, resulting in a "pure" innovative drug index with a 100% purity rate [1] Group 2 - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, with a net inflow of 540 million yuan in the past month, doubling its size to 1.17 billion yuan compared to a month ago, providing investors with precise opportunities for industry development [2]

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]

Group 1 - The Hang Seng Biotechnology ETF (159615) has risen by 2.92% as of August 13, 2025, with an active trading volume of 1.26 billion yuan and a turnover rate of 36.28% [1] - The Hang Seng Biotechnology Index, which the ETF tracks, increased by 3.39%, with notable gains from constituent stocks such as CanSino Biologics (up 8.52%), WuXi AppTec (up 7.34%), and Innovent Biologics (up 6.07%) [1] - As of August 12, the ETF saw a net inflow of 2.5381 million yuan, with a total net inflow of 20.5331 million yuan over the last five trading days, indicating a positive investment sentiment [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drug names passing the commercial insurance innovative drug directory review [1] - High-priced innovative drugs, including CAR-T cancer treatment, are seeking inclusion in the commercial insurance innovative drug directory, aiming for diversified payment options for innovative drugs [1] - CITIC Securities expresses a long-term positive outlook on the innovative drug sector, emphasizing the importance of innovation-driven strategies, internationalization, and reforms in outpatient marketing models [1] Group 3 - The Hang Seng Biotechnology Index reflects the overall performance of the largest 50 biotechnology companies listed in Hong Kong, including major stocks like BeiGene, Innovent Biologics, and WuXi Biologics [2]

8月13日，石药集团(01093)盘中上涨2.49%，截至10:32，报10.29元/股，成交3.01亿元。 8月12日，天风证券首次给予买入评级,目标价18.63港元。 本文源自：金融界 作者：行情君 石药集团有限公司是香港的一家医药上市企业，主要业务为成药和原料药生产，并以创新药为核心发展 战略，在神经系统疾病、抗肿瘤、抗感染及心血管疾病等治疗领域具有强大的产品组合。同时该公司拥 有一支国际化的研发团队，专注于小分子靶向药物、纳米药物、单抗药物、双抗药物、抗体偶联药物以 及免疫领域生物药物的发现、研究及开发。 截至2025年一季报，石药集团营业总收入70.15亿元、净利润14.78亿元。 ...

Core Insights - The Hang Seng Healthcare Index (HSHCI) has shown a strong increase of 1.66%, with notable gains in constituent stocks such as Weigao (9.05%) and Innovent Biologics (4.41%) [3] - The Hang Seng Medical ETF (513060) has risen by 0.89%, with a recent price of 0.68 yuan, and has accumulated a 15.41% increase over the past month, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) has also increased by 1.63%, with significant contributions from stocks like Innovent Biologics and Kangtai Biologicals [5] Market Dynamics - The National Healthcare Security Administration has announced the preliminary review of 121 innovative drugs for inclusion in the commercial insurance innovative drug directory, which is expected to enhance payment accessibility and commercial expectations for these products [5][6] - The medical device sector is experiencing positive sentiment due to clear technological routes and industrialization goals for brain-computer interfaces, which are expected to boost high-end medical equipment and surgical robotics [6] Investment Trends - The innovative drug sector has seen significant year-to-date gains, leading to some profit-taking and short-term volatility, while the medical device sector is attracting marginal inflows due to favorable policies and industry trends [7] - Analysts suggest focusing on companies with strong cash flow and commercial certainty in the innovative drug space, while the medical device sector is recommended for its policy-driven opportunities [8] ETF Performance - The Hang Seng Medical ETF has a current scale of 73.29 billion yuan, ranking in the top third among comparable funds, with a net value increase of 39.30% over the past two years [11][12] - The ETF has demonstrated a maximum monthly return of 28.34% since inception, with an average monthly return of 7.42% [12] - The Hang Seng Medical ETF has a tracking error of 0.060%, the highest precision among comparable funds, and its latest P/E ratio is 29.88, indicating a historical low valuation [16] Fund Characteristics - The Hong Kong Innovative Drug Selection ETF (520690) has seen a significant increase in scale, with a recent size growth of 27.29 million yuan, ranking in the top half among comparable funds [18] - The ETF has achieved a new high in shares at 404 million, with continuous net inflows over the past four days [19] - The management fee for both ETFs is 0.50%, with the Hong Kong Innovative Drug Selection ETF having the lowest custody fee at 0.10% among comparable funds [21]

Group 1: Market Overview - The Hang Seng Index closed up 62 points or 0.25%, ending at 24,969, after fluctuating around the 25,000 level throughout the day [3][4] - The total market turnover was 215.42 billion, with a net inflow of 9.45 billion from northbound trading [3] - The technology index fell by 0.38%, indicating weakness in tech stocks, while the national index rose by 0.32% [3][4] Group 2: IPO Market - Hong Kong's IPO market is leading globally, with a total of 53 new listings in the first seven months of the year, raising approximately 127 billion, a year-on-year increase of over six times [7] - The strong performance is attributed to steady regulatory improvements and market reforms, with expectations for further developments in the second half of the year [7] Group 3: Company News - 康基医疗 (康基医疗) announced a privatization offer at a cash price of 9.25 HKD per share, representing a premium of about 9.9% over the last closing price [12] - 毛戈平 (毛戈平) expects a net profit growth of 35% to 37% for the first half of the year, driven by strong brand recognition and consumer demand [13] - 朗廷 (朗廷) reported a 17.65% decline in interim distributable income, with hotel revenue down 4.58%, citing geopolitical tensions and changing consumer behavior as key challenges [14] - 康健国际医疗 (康健国际医疗) anticipates turning a profit for the first half of the year, with expected earnings between 9.1 million to 14.3 million, compared to a loss of 47.7 million in the same period last year [15]

Summary of Madrigal Pharmaceuticals (MDGL) FY Conference Call - August 12, 2025 Company Overview - **Company**: Madrigal Pharmaceuticals (MDGL) - **Product**: ResDiffera, a treatment for NASH (Non-Alcoholic Steatohepatitis) Key Industry Insights - **NASH Market**: The NASH market is expected to grow significantly, with Madrigal positioned as a leader due to its first approved drug in this space. - **Patient Population**: Approximately 245,000 patients with F4C (compensated cirrhosis) and 315,000 patients with F2F3 NASH are targeted, with a focus on deeper penetration in the F4C group due to their higher medical needs. Core Points and Arguments 1. **Patent Protection**: A new US patent extends protection until February 2045, providing a significant competitive advantage and allowing for strategic planning of future pipelines [3][17][18]. 2. **Sales Performance**: The company reported $213 million in sales for the last quarter, annualizing to over $800 million, with 80% of top targets prescribing ResDiffera [5][6]. 3. **Patient Adoption**: Over 23,000 patients are currently on therapy, indicating strong adoption and positive feedback from healthcare providers [5][6]. 4. **Clinical Efficacy**: Positive feedback from hepatologists indicates that ResDiffera is exceeding expectations in improving liver stiffness and other health metrics [9][10][11]. 5. **Commercial Strategy**: The company is focused on long-term education for providers and patients, ensuring understanding of NASH and the benefits of ResDiffera [13][14][15]. 6. **Combination Therapy**: The recent acquisition of an oral GLP-1 to combine with ResDiffera is expected to enhance efficacy by reducing liver fat and improving patient outcomes [35][36][37]. 7. **Market Positioning**: ResDiffera is positioned as a first-line therapy in EASL guidelines, with a strategic approach to launch in Germany and other European countries [49][50]. Additional Important Insights - **Real-World Data**: The company is leveraging real-world data from the US launch to inform its European strategy, aiming for a smooth rollout [51]. - **Off-Label Use**: There is some off-label use of ResDiffera in F4 patients, but the company is cautious about this until further study results are available [31][32]. - **Future Studies**: The Maestro Outcomes study is expected to provide further validation of ResDiffera's efficacy in 2027, which will be crucial for market confidence [26][30]. This summary encapsulates the key points discussed during the conference call, highlighting Madrigal Pharmaceuticals' strategic initiatives, market positioning, and the promising outlook for ResDiffera in the NASH treatment landscape.

格隆汇8月12日丨石药集团(01093.HK)宣布，公司董事会会议将于2025年8月22日(星期五)举行，藉以(其 中包括)批准公司及其附属公司截至2025年6月30日止6个月的未经审核中期业绩。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 代表董事會 石藥集團有限公司 主席 蔡東晨 香港，2025年8月12日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 蔡 東 晨 先 生 、 張 翠 龍 先 生 、 王 振 國 先 生 、 潘 衛 東 先 生、王懷玉先生、李春雷博士、姚兵博士、蔡鑫先生及陳衛平先生；及獨立非執行董事王 波先生、CHEN Chuan先生、王宏廣教授、歐振國先生、羅卓堅先生及李泉女士。 （於香港註冊成立之有限公司） （股份代號：1093） 董事會召開日期 石藥集團有限公司（「本公司」）宣布，本公司董事會（「董事會」）會議將於2025年8月22日（ 星 期五 ）舉行，藉以（ 其中包括 ）批准本公司及其附屬公司截至2025年6月30日止6個月之未經 審核中期業績。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 ...

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing up 0.25% at 24,969.68 points and a total trading volume of HKD 215.42 billion [1] - The Hang Seng China Enterprises Index rose by 0.32% to 8,916.85 points, while the Hang Seng Tech Index fell by 0.38% to 5,439.16 points [1] Blue Chip Performance - Semiconductor company SMIC (00981) led the blue-chip stocks, rising 5.03% to HKD 51.15, contributing 17.41 points to the Hang Seng Index [2] - Other notable blue-chip performers included Zhongsheng Holdings (00881) up 4.01% and Orient Overseas International (00316) up 3.13% [2] Sector Highlights - Semiconductor stocks rebounded, with SMIC and Huahong Semiconductor both gaining over 5% [3] - The insurance sector saw significant gains, with China Pacific Insurance (02601) up 6.2% and New China Life Insurance (01336) up 3.86% [5][6] - Coal stocks were active, with China Shenhua Energy (01088) rising 3% and Yanzhou Coal Mining (01171) up 2.95% [6] Emerging Trends - The global semiconductor market is expected to continue its optimistic growth trajectory, driven by AI and domestic demand [4] - The dairy sector showed strong performance, with Aoyuan Group (02425) surging 43.15% [4] - The insurance industry is adjusting to a new regulatory environment, with a decrease in preset interest rates expected to lower costs for new business liabilities [6] Notable Stock Movements - Zhonghui Biotech (02627) surged 31.31% due to strong demand for its vaccine products [7] - Fosun International (00656) rose 13.3% following news of its application for a stablecoin license [8] - Chongqing Machinery (02722) announced a profit increase of approximately 50% for the first half of the year, leading to a 5.92% rise in its stock price [10] - Jin Sangzi (06896) experienced a significant drop of 23.64% due to a profit warning, anticipating a 37% decrease in profit compared to the previous year [11]